	Application No.	Applicant(s)
Notice of Allowability	10/676,782 Examiner	MANTELL ET AL.  Art Unit
	LAdiminer	Art ontic
	Devesh Khare	1623
The MAILING DATE of this communication appears on the cover sheet with the correspondence address-, All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>10/17/2005</u> .		
2. The allowed claim(s) is/are 58 and 78.		
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)  All b)  Some* c)  None of the:</li> </ul>		
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>		
2. Certified copies of the priority documents have been received in Application No.		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		•
Attachment(s)	5 Notice of Informal D	atent Application (PTO-152)
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	6. ☐ Interview Summary	,,
	Paper No./Mail Dat	è
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 10/17/2005</li> </ol>	08), 7. ☐ Examiner's Amendr	nenvComment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. X Examiner's Stateme	ent of Reasons for Allowance
or biological iviaterial	9.	JAMES O. WILSON
	√S	UPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1800

**Notice of Allowability** 

Part of Paper No./Mail Date 20051122

U.S. Patent and Trademark Office PTOL-37 (Rev. 7-05) Art Unit: 1623

The amendments and remarks received on 10/17/2005 have been entered. Claim 58 has been amended. Claim 61 has been cancelled. Claims 1-57 and 59-77 have been cancelled previously. New claim 78 has been added.

The rejection under 35 U.S.C. 112, first paragraph of the Office Action mailed on 07/13/2005, has been overcome through applicants' amendments.

Claims 58 and 78 are currently pending in this application.

Claims 58 and 78 are allowed.

2. The following is an examiner's statement of reasons for allowance: Claims 58 and 78 are drawn to a method of treating an inflammatory disease in a mammal comprising administering to said mammal in need of such treatment an effective amount of adenosine derivative of formula (I) (claim 58); it is noted that said adenosine derivatives and the composition thereof issued in the U.S. Patent No. 6,753,322 B2, is assigned to the assignee of this invention, is not taught or fairly suggested by the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-1235.

Devesh Khare, Ph.D.,J.D.

Art Unit 1623

November 22, 2005

JAMES O. WILSON

TECHNOLOGY CENTER 1000

Page 2